Trevena, Inc. (TRVN) Appoints Adam M. Koppel To The Board Of Directors
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Adam M. Koppel, M.D., Ph.D. has joined Trevena's Board of Directors. Dr. Koppel replaces Christopher Mirabelli, Ph.D., managing director at HealthCare Ventures, who is stepping down from the Board following the Company's recent initial public offering.